Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 40
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

  • Sánchez-Guixé, Mònica
  • Muiños, Ferran
  • Pinheiro Santin, Morena
  • González-Huici, Víctor
  • Rodríguez-Hernández, Carlos
  • Avgustinova, Alexandra
  • Lavarino, Cinzia
  • González-Pérez, Abel
  • Mora, Jaume
  • López Bigas, Núria
Pediatric cancers are rare diseases, and children without known germline predisposing conditions who develop a second malignancy during developmental ages are extremely rare. We present four such clinical cases and, through whole-genome and error-correcting ultra-deep duplex sequencing of tumor and normal samples, we explored the origin of the second malignancy in four children, uncovering different routes of development. The exposure to cytotoxic therapies was linked to the emergence of a secondary acute myeloid leukemia. A common somatic mutation acquired early during embryonic development was the driver of two solid malignancies in another child. In two cases, the two tumors developed from completely independent clones diverging during embryogenesis. Importantly, we demonstrate that platinum-based therapies contributed at least one order of magnitude more mutations per day of exposure than aging to normal tissues in these children., N. Lopez-Bigas acknowledges funding from the European Research Council (consolidator grant 682398). M. Sanchez-Guixe was supported by a postdoctoral contract with the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). This project was supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI 10.13039/501100011033/. It has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMI­NENT) funded by Cancer Research UK (CGCATF-2021/100008), NCI (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). We are grateful to the Band of Parents at Hospital Sant Joan de Déu Barcelona for supporting the overall research activities of the developmental tumor laboratory, PCCB, and for having generously contributed with their samples. This study would have been impossible to reach without this contribution.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Hotspot propensity across mutational processes

  • Arnedo Pac, Claudia
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
The sparsity of mutations observed across tumours hinders our ability to study mutation rate variability at nucleotide resolution. To circumvent this, here we investigated the propensity of mutational processes to form mutational hotspots as a readout of their mutation rate variability at single base resolution. Mutational signatures 1 and 17 have the highest hotspot propensity (5-78 times higher than other processes). After accounting for trinucleotide mutational probabilities, sequence composition and mutational heterogeneity at 10 Kbp, most (94-95%) signature 17 hotspots remain unexplained, suggesting a significant role of local genomic features. For signature 1, the inclusion of genome-wide distribution of methylated CpG sites into models can explain most (80-100%) of the hotspot propensity. There is an increased hotspot propensity of signature 1 in normal tissues and de novo germline mutations. We demonstrate that hotspot propensity is a useful readout to assess the accuracy of mutation rate models at nucleotide resolution. This new approach and the findings derived from it open up new avenues for a range of somatic and germline studies investigating and modelling mutagenesis., This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation has made available to the study. We acknowledge the technical contributions of Iker Reyes-Salazar and Loris Mularoni to HotspotFinder algorithm and annotations. NL-B acknowledges funding from the European Research Council (consolidator grant 682398) and the European Regional Development Fund/Spanish Ministry of Science, Innovation and Universities—Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Fundación Científica Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). This work has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMINENT) funded by Cancer Research UK (CGCATF-2021/100008), National Cancer Institute (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). CA-P was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

  • Rheinbay, Esther
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • González-Pérez, Abel
  • Pich Roselló, Oriol, 1992-
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Getz, Gad
  • PCAWG Consortium
The discovery of drivers of cancer has traditionally focused on protein-coding genes1-4. Here we present analyses of driver point mutations and structural variants in non-coding regions across 2,658 genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium5 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). For point mutations, we developed a statistically rigorous strategy for combining significance levels from multiple methods of driver discovery that overcomes the limitations of individual methods. For structural variants, we present two methods of driver discovery, and identify regions that are significantly affected by recurrent breakpoints and recurrent somatic juxtapositions. Our analyses confirm previously reported drivers6,7, raise doubts about others and identify novel candidates, including point mutations in the 5' region of TP53, in the 3' untranslated regions of NFKBIZ and TOB1, focal deletions in BRD4 and rearrangements in the loci of AKR1C genes. We show that although point mutations and structural variants that drive cancer are less frequent in non-coding genes and regulatory sequences than in protein-coding genes, additional examples of these drivers will be found as more cancer genomes become available., Work in the Getz laboratory was partially funded by the GDAC grants (NIH U24CA143845 and NIH U24CA210999), G.G.’s funds at the Broad Institute and MGH. J.S.P. was partially funded by Independent Research Fund Denmark (12-126439 and 7016-00379) and The Danish Cancer Society (R124-A7869). R.B. received funds from the National Institutes of Health (U54CA143798, R01CA188228, R35GM127029, and R01CA215489). J.W. was partly funded by Independent Research Fund Denmark (4183-00233B and 8020-00282B) and Danish Cancer Society (R147-Rp12977). N.L.-B. acknowledges funding from the European Research Council consolidator grant 682398) and Spanish Ministry of Economy and Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The repertoire of mutational signatures in human cancer

  • Alexandrov, Ludmil B.
  • López Bigas, Núria
  • PCAWG Consortium
Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature1. Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium2 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses3-15, enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated-but distinct-DNA damage, repair and/or replication mechanisms. By estimating the contribution of each signature to the mutational catalogues of individual cancer genomes, we revealed associations of signatures to exogenous or endogenous exposures, as well as to defective DNA-maintenance processes. However, many signatures are of unknown cause. This analysis provides a systematic perspective on the repertoire of mutational processes that contribute to the development of human cancer., This work was supported by Wellcome grant reference 206194 (M.R.S.), Singapore National Medical Research Council grants NMRC/CIRG/1422/2015 and MOH-000032/MOH-CIRG18may-0004 and the Singapore Ministry of Health via the Duke-NUS Signature Research Programmes (M.N.H., A.W.T.N., Y.W., A.B. and S.G.R.), US National Institute of Health Intramural Research Program Project Z1AES103266 (D.A.G.), the European Research Council Consolidator Grant 682398 (N.L.-B.), US National Cancer Institute U24CA143843 (D.A.W.) and Cancer Research UK Grand Challenge Award C98/A24032 (E.N.B., S.M.A.I., L.B.A. and M.R.S.). G.G and J.K were partially supported by the National Cancer Institute grants U24CA210999 and U24CA143845. G.G. was partially supported by the Paul C. Zamecnick, MD, Chair in Oncology at the Massachusetts General Hospital Cancer Center. N.J.H. and G.G. were partially supported by G.G.’s funds at the Broad Institute and Massachusetts General Hospital. N.J.H. was partially funded by the Molecular Biophysics Training Grant NIH/ NIGMS T32 GM008313 (PI: Venkatesh N. Murthy).We acknowledge the contributions of the many clinical networks across the ICGC and TCGA who provided samples and data to the PCAWG Consortium, and the contributions of the Technical Working Group and the Germline Working Group of the PCAWG Consortium for collation, realignment and harmonized variant calling of the cancer genomes used in this study.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero Noguera, David
  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Schroeder, Michael Philipp, 1986-
  • Vivancos Prellezo, Ana
  • Rovira Guerín, Ana
  • Tusquets Trias de Bes, Ignacio
  • Albanell Mestres, Joan
  • Rodon, Jordi
  • Tabernero Cartula, Josep
  • Torres, Carmen de
  • Dienstmann, Rodrigo
  • González-Pérez, Abel
  • López Bigas, Núria
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org., This project has received funding from Fundació La Marató de TV3, the European Union's Horizon 2020 research and innovation programme 2014-2020 under grant agreement number 634143, and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). DT is supported by project SAF2015-74072-JIN funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). CR-P is funded by a FPI MINECO grant (BES-2013-063354). AG-P is supported by a Ramon y Cajal fellowship (RYC-2013-14554).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

OpenVariant: a toolkit to parse and operate multiple input file formats

  • Martínez-Millán, David
  • Brando, Federica
  • Grau, Miguel L.
  • Sánchez-Guixé, Mònica
  • López Elorduy, Carlos
  • Reyes-Salazar, Iker
  • Deu-Pons, Jordi
  • López Bigas, Núria
  • González-Pérez, Abel
Summary: Advances in high-throughput DNA sequencing technologies and decreasing costs have fueled the identification of small genetic variants (such as single nucleotide variants and indels) across tumors. Despite efforts to standardize variant formats and vocabularies, many sources of variability persist across databases and computational tools that annotate variants, hindering their integration within cancer genomic analyses. In this context, we present OpenVariant, an easily extendable Python package that facilitates seamless reading, parsing and refinement of diverse input file formats in a customizable structure, all within a single process. Availability and implementation: OpenVariant is an open-source package available at https://github.com/bbglab/openvariant. Documentation may be found at https://openvariant.readthedocs.io., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]. This project has received funding from the European Union’s Horizon Europe programme [grant agreement CGI-Clinics 101057509]. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociación Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). This work has also been funded by the Institute of Health Carlos III [project IMPaCT-Data, exp. IMP/00019], co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Reduced mutation rate in exons due to differential mismatch repair

  • Frigola, Joan
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • Muiños, Ferran
  • Gonzalez-Perez, Abel
  • López Bigas, Núria
While recent studies have identified higher than anticipated heterogeneity of mutation rate across genomic regions, mutations in exons and introns are assumed to be generated at the same rate. Here we find fewer somatic mutations in exons than expected from their sequence content and demonstrate that this is not due to purifying selection. Instead, we show that it is caused by higher mismatch-repair activity in exonic than in intronic regions. Our findings have important implications for understanding of mutational and DNA repair processes and knowledge of the evolution of eukaryotic genes, and they have practical ramifications for the study of evolution of both tumors and species., We acknowledge funding from Spanish Ministry of Economy and Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE), La Fundació la Marató de TV3, EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). R. Sabarinathan is supported by an EMBO Long-Term Fellowship (ALTF 568-2014) co-funded by the European Commission (EMBOCOFUND2012, GA-2012-600394) support from Marie Curie Actions. A.Gonzalez-Perez is supported by a Ramón y Cajal contract
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

  • Wagner, Alex H.
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Variant Interpretation for Cancer Consortium
Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases., We acknowledge the contributions from members of GA4GH and specifically the Genotype to Phenotype Task Team for their numerous contributions leading to this study. We thank the VICC knowledgebase partners for their input in construction of the meta-knowledgebase and drafting of the paper, M. McCoy for his assistance in proofreading the manuscript and J. McMichael for his work in restyling Fig. 1. A.H.W. was supported by NIH National Cancer Institute (NCI) award F32CA206247 and National Human Genome Research Institute (NHGRI) award K99HG010157. B.W. was supported by NIH NHGRI award U54HG007990, NIH NCI R01CA180778 and Intel SRA-16-037. D.T.R. is a participant in the Berlin Institute of Health—Charité Clinical Scientist Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health, and was supported by grant nos. 031L0030E and 031L0023 awarded by the German Federal Ministry of Education and Research. D.I.R. and S.M. are supported by ClinGen, through the NHGRI awards U41HG006834, U41HG009649, U41HG009650 and U01HG007437. T.A. was supported by an award from Academy of Finland (grant no. 330857), Cancer Society of Finland. M.H. was supported by the Monarch Initiative NIH Office of Director award R24OD011883. J. Gao, D.C. and N.S. were supported by NIH NCI award P30CA008748. N.L.B. acknowledges funding from the European Research Council (consolidator grant 682398). M.L. was supported through the Medical Research Council—Cancer Research UK Stratification in Colorectal Cancer Program grant and Health Data Research UK Substantive Site grant. M.G. was supported by NIH NHGRI award R00HG007940 and a V Scholar Award from the V Foundation for Cancer Research. O.L.G., M.G. and the CIViC knowledgebase were supported by the NIH NCI awards U01CA209936 and U24CA237719 and a Cancer Moonshot funding opportunity, specifically an Activities to Promote Technology Research Collaborations for Cancer Research (Administrative Support) award.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The genomic landscape of 2,023 colorectal cancers

  • Cornish, Alex J.
  • Arnedo Pac, Claudia
  • López Bigas, Núria
  • Houlston, Richard S.
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11-13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care., R.S.H., I.P.M.T. and N.L.-B. are supported by the Wellcome Trust (214388), T.A.G. and A.S are supported by the Wellcome Trust (202778/B/16/Z). I.P.M.T. is supported by Cancer Research UK (C6199/A27327). R.S.H. is supported by Cancer Research UK (C1298/A8362). D.C.W. is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). A. Sottoriva is supported by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771 and DRCNPG-May21\100001). P.Q. and H.M.W. are supported by Cancer Research UK Grand Challenge Initiative (OPTIMISTICC C10674/A27140). P.Q. is also supported by Yorkshire Cancer Research L386 and is a National Institute of Health Senior Investigator. B.N was funded through the Cancer Research UK Birmingham Centre award (C17422/A25154). C.A.-P. was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011). L.B.A was supported by grants from the US National Institutes of Health, including NIEHS R01ES032547 and NCI R01CA269919. G.C. is supported by the Italian Association for Cancer Research (AIRC) under MFAG 2020-ID 24913. We acknowledge funding from the National Institute of Health (NCI U54 CA217376) to A.S and T.A.G. This work was also supported by a Wellcome Trust award to the Centre for Evolution and Cancer at the ICR (105104/Z/14/Z). D.N.C. is supported a by Cancer Research UK Advanced Clinician Scientist Fellowship award (C26642/A27963). D.N.C., D.C.W. and A.F. acknowledge support from the Oxford NIHR Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We are grateful to all participants and other individuals involved in the study.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The evolution of relapse of adult T cell acute lymphoblastic leukemia

  • Sentís, Inés
  • González, Santi
  • Genescà, Eulalia
  • García Hernández, Violeta
  • Muiños, Ferran
  • González, Celia
  • López Arribillaga, Erika, 1986-
  • González, Jessica
  • Fernández-Ibarrondo, Lierni
  • Mularoni, Loris
  • Espinosa-Anke, Luis
  • Bellosillo Paricio, Beatriz
  • Ribera, Josep Maria
  • Bigas Salvans, Anna
  • González-Pérez, Abel
  • López Bigas, Núria
Background: Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. A higher percentage of the adult patients relapse, compared to children. It is thus essential to study the mechanisms of relapse of adult T-ALL cases. Results: We profile whole-genome somatic mutations of 19 primary T-ALLs from adult patients and the corresponding relapse malignancies and analyze their evolution upon treatment in comparison with 238 pediatric and young adult ALL cases. We compare the mutational processes and driver mutations active in primary and relapse adult T-ALLs with those of pediatric patients. A precise estimation of clock-like mutations in leukemic cells shows that the emergence of the relapse clone occurs several months before the diagnosis of the primary T-ALL. Specifically, through the doubling time of the leukemic population, we find that in at least 14 out of the 19 patients, the population of relapse leukemia present at the moment of diagnosis comprises more than one but fewer than 108 blasts. Using simulations, we show that in all patients the relapse appears to be driven by genetic mutations. Conclusions: The early appearance of a population of leukemic cells with genetic mechanisms of resistance across adult T-ALL cases constitutes a challenge for treatment. Improving early detection of the malignancy is thus key to prevent its relapse., The authors would like to thank the Asociación Española Contra el Cáncer (AECC) for financially supporting this project (GC16173697BIGA). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and the ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00). S. G work is supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 754510. I. S is supported by FPI fellowship from Spanish Ministry of Economy and Competitiveness (project reference SAF2015-66084-R). V.G-H. is supported by the AECC (project reference GC16173697BIGA-9). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers

  • Arnedo Pac, Claudia
  • Mularoni, Loris
  • Muiños, Ferran
  • Gonzalez-Perez, Abel
  • López Bigas, Núria
Motivation: Identification of the genomic alterations driving tumorigenesis is one of the main goals in oncogenomics research. Given the evolutionary principles of cancer development, computational methods that detect signals of positive selection in the pattern of tumor mutations have been effectively applied in the search for cancer genes. One of these signals is the abnormal clustering of mutations, which has been shown to be complementary to other signals in the detection of driver genes. Results: We have developed OncodriveCLUSTL, a new sequence-based clustering algorithm to detect significant clustering signals across genomic regions. OncodriveCLUSTL is based on a local background model derived from the simulation of mutations accounting for the composition of tri- or penta-nucleotide context substitutions observed in the cohort under study. Our method can identify known clusters and bona-fide cancer drivers across cohorts of tumor whole-exomes, outperforming the existing OncodriveCLUST algorithm and complementing other methods based on different signals of positive selection. Our results indicate that OncodriveCLUSTL can be applied to the analysis of non-coding genomic elements and non-human mutations data. Availability and implementation: OncodriveCLUSTL is available as an installable Python 3.5 package. The source code and running examples are freely available at https://bitbucket.org/bbglab/oncodriveclustl under GNU Affero General Public License. Supplementary information: Supplementary data are available at Bioinformatics online., This work was supported by funding from the Spanish Ministry of Economy and Competitiveness [SAF2015-66084-R, MINECO/FEDER, UE] and by the European Research Council [Consolidator Grant 68239]. IRB Barcelona is the recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). A.G.-P. is supported by a Ramón y Cajal contract from the Spanish Ministry of Economy and Competitiveness [RYC-2013-1455]. C.A.-P. is supported by “la Caixa” Foundation (ID 100010434) with code [LCF/BQ/ES18/11670011].
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A compendium of mutational cancer driver genes

  • Martínez Jiménez, Francisco
  • Kranas, Hanna
  • Gonzalez Perez, Abel
  • López Bigas, Núria
  • Muiños, Ferran
  • Sentís, Inés
  • Deu Pons, Jordi
  • Reyes Salazar, Iker
  • Arnedo Pac, Claudia
  • Mularoni, Loris
  • Pich, Oriol
  • Bonet, José
A fundamental goal in cancer research is to understand the mechanisms of cell transformation. This is key to developing more efficient cancer detection methods and therapeutic approaches. One milestone towards this objective is the identification of all the genes with mutations capable of driving tumours. Since the 1970s, the list of cancer genes has been growing steadily. Because cancer driver genes are under positive selection in tumorigenesis, their observed patterns of somatic mutations across tumours in a cohort deviate from those expected from neutral mutagenesis. These deviations, which constitute signals of positive selection, may be detected by carefully designed bioinformatics methods, which have become the state of the art in the identification of driver genes. A systematic approach combining several of these signals could lead to a compendium of mutational cancer genes. In this Review, we present the Integrative OncoGenomics (IntOGen) pipeline, an implementation of such an approach to obtain the compendium of mutational cancer drivers. Its application to somatic mutations of more than 28,000 tumours of 66 cancer types reveals 568 cancer genes and points towards their mechanisms of tumorigenesis. The application of this approach to the ever-growing datasets of somatic tumour mutations will support the continuous refinement of our knowledge of the genetic basis of cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Somatic and Germline Mutation Periodicity Follow the Orientation of the DNA Minor Groove around Nucleosomes

  • Pich, Oriol
  • Muiños, Ferran
  • Sabarinathan, Radhakrishnan
  • Reyes Salazar, Iker
  • González Pérez, Abel
  • López Bigas, Núria
Mutation rates along the genome are highly variable and influenced by several chromatin features. Here, we addressed how nucleosomes, the most pervasive chromatin structure in eukaryotes, affect the generation of mutations. We discovered that within nucleosomes, the somatic mutation rate across several tumor cohorts exhibits a strong 10 base pair (bp) periodicity. This periodic pattern tracks the alternation of the DNA minor groove facing toward and away from the histones. The strength and phase of the mutation rate periodicity are determined by the mutational processes active in tumors. We uncovered similar periodic patterns in the genetic variation among human and Arabidopsis populations, also detectable in their divergence from close species, indicating that the same principles underlie germline and somatic mutation rates. We propose that differential DNA damage and repair processes dependent on the minor groove orientation in nucleosome-bound DNA contribute to the 10-bp periodicity in AT/CG content in eukaryotic genomes.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Whole-genome landscapes of major melanoma subtypes

  • Hayward, Nicholas K.
  • Wilmott, James S.
  • Waddell, Nicola
  • Johansson, Peter A.
  • Field, Matthew A.
  • Nones, Katia
  • Patch, Ann-Marie
  • Kakavand, Hojabr
  • Alexandrov, Ludmil B.
  • Burke, Hazel
  • Jakrot, Valerie
  • Kazakoff, Stephen
  • Holmes, Oliver
  • Leonard, Conrad
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • Wood, Scott
  • Xu, Qinying
  • Waddell, Nick
  • Tembe, Varsha
  • Pupo, Gulietta M.
  • Paoli-Iseppi, Ricardo De
  • Vilain, Ricardo E.
  • Shang, Ping
  • Lau, Loretta M.S.
  • Dagg, Rebecca A.
  • Schramm, Sarah-Jane
  • Pritchard, Antonia
  • Dutton-Regester, Ken
  • Newell, Felicity
  • Fitzgerald, Anna
  • Shang, Catherine A.
  • Grimmond, Sean M.
  • Pickett, Hilda A.
  • Yang, Jean Y.
  • Stretch, Jonathan R.
  • Behren, Andreas
  • Kefford, Richard F.
  • Hersey, Peter
  • Long, Georgina V.
  • Cebon, Jonathan
  • Shackleton, Mark
  • Spillane, Andrew J.
  • Saw, Robyn P. M.
  • López Bigas, Núria
  • Pearson, John V.
  • Thompson, John F.
  • Scolyer, Richard A.
  • Mann, Graham J.
Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero Noguera, David
  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Schroeder, Michael Philipp, 1986-
  • Vivancos Prellezo, Ana
  • Rovira Guerín, Ana
  • Tusquets Trias de Bes, Ignacio
  • Albanell Mestres, Joan
  • Rodon, Jordi
  • Tabernero Cartula, Josep
  • Torres, Carmen de
  • Dienstmann, Rodrigo
  • González-Pérez, Abel
  • López Bigas, Núria
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org., This project has received funding from Fundació La Marató de TV3, the European Union's Horizon 2020 research and innovation programme 2014-2020 under grant agreement number 634143, and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). DT is supported by project SAF2015-74072-JIN funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). CR-P is funded by a FPI MINECO grant (BES-2013-063354). AG-P is supported by a Ramon y Cajal fellowship (RYC-2013-14554).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The evolution of relapse of adult T cell acute lymphoblastic leukemia

  • Sentís, Inés
  • González, Santi
  • Genescà, Eulalia
  • García Hernández, Violeta
  • Muiños, Ferran
  • González, Celia
  • López Arribillaga, Erika, 1986-
  • González, Jessica
  • Fernández-Ibarrondo, Lierni
  • Mularoni, Loris
  • Espinosa-Anke, Luis
  • Bellosillo Paricio, Beatriz
  • Ribera, Josep Maria
  • Bigas Salvans, Anna
  • González-Pérez, Abel
  • López Bigas, Núria
Background: Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. A higher percentage of the adult patients relapse, compared to children. It is thus essential to study the mechanisms of relapse of adult T-ALL cases. Results: We profile whole-genome somatic mutations of 19 primary T-ALLs from adult patients and the corresponding relapse malignancies and analyze their evolution upon treatment in comparison with 238 pediatric and young adult ALL cases. We compare the mutational processes and driver mutations active in primary and relapse adult T-ALLs with those of pediatric patients. A precise estimation of clock-like mutations in leukemic cells shows that the emergence of the relapse clone occurs several months before the diagnosis of the primary T-ALL. Specifically, through the doubling time of the leukemic population, we find that in at least 14 out of the 19 patients, the population of relapse leukemia present at the moment of diagnosis comprises more than one but fewer than 108 blasts. Using simulations, we show that in all patients the relapse appears to be driven by genetic mutations. Conclusions: The early appearance of a population of leukemic cells with genetic mechanisms of resistance across adult T-ALL cases constitutes a challenge for treatment. Improving early detection of the malignancy is thus key to prevent its relapse., The authors would like to thank the Asociación Española Contra el Cáncer (AECC) for financially supporting this project (GC16173697BIGA). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and the ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00). S. G work is supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 754510. I. S is supported by FPI fellowship from Spanish Ministry of Economy and Competitiveness (project reference SAF2015-66084-R). V.G-H. is supported by the AECC (project reference GC16173697BIGA-9). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites

  • Sabarinathan, Radhakrishnan
  • Lopez-Bigas, Nuria
  • Frigola Rissech, Joan
  • Gonzalez-Perez, Abel
Llocs d’unió; Dany en l'ADN; Factor de transcripció, Sitios de unión; Daño en el ADN; Factor de transcripcion, Binding sites; Dna damage; Transcription factor, An abnormally high rate of UV-light related mutations appears at transcription factor binding sites (TFBS) across melanomas. The binding of transcription factors (TFs) to the DNA impairs the repair of UV-induced lesions and certain TFs have been shown to increase the rate of generation of these lesions at their binding sites. However, the precise contribution of these two elements to the increase in mutation rate at TFBS in these malignant cells is not understood. Here, exploiting nucleotide-resolution data, we computed the rate of formation and repair of UV-lesions within the binding sites of TFs of different families. We observed, at certain dipyrimidine positions within the binding site of TFs in the Tryptophan Cluster family, an increased rate of formation of UV-induced lesions, corroborating previous studies. Nevertheless, across most families of TFs, the observed increased mutation rate within the entire DNA region covered by the protein results from the decreased repair efficiency. While the rate of mutations across all TFBS does not agree with the amount of UV-induced lesions observed immediately after UV exposure, it strongly agrees with that observed after 48 h. This corroborates the determinant role of the impaired repair in the observed increase of mutation rate., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]; Spanish Ministry of Economy and Competitiveness [SAF2015-66084-R, MINECO/FEDER to U.E.]; IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya); R.S. acknowledges funding support from the National Centre for Biological Sciences (NCBS-TIFR), Bangalore, India. Funding for open access charge: Spanish Ministry of Economy and Competitiveness.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

  • Rheinbay, Esther
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • González-Pérez, Abel
  • Pich Roselló, Oriol, 1992-
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Getz, Gad
  • PCAWG Consortium
The discovery of drivers of cancer has traditionally focused on protein-coding genes1-4. Here we present analyses of driver point mutations and structural variants in non-coding regions across 2,658 genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium5 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). For point mutations, we developed a statistically rigorous strategy for combining significance levels from multiple methods of driver discovery that overcomes the limitations of individual methods. For structural variants, we present two methods of driver discovery, and identify regions that are significantly affected by recurrent breakpoints and recurrent somatic juxtapositions. Our analyses confirm previously reported drivers6,7, raise doubts about others and identify novel candidates, including point mutations in the 5' region of TP53, in the 3' untranslated regions of NFKBIZ and TOB1, focal deletions in BRD4 and rearrangements in the loci of AKR1C genes. We show that although point mutations and structural variants that drive cancer are less frequent in non-coding genes and regulatory sequences than in protein-coding genes, additional examples of these drivers will be found as more cancer genomes become available., Work in the Getz laboratory was partially funded by the GDAC grants (NIH U24CA143845 and NIH U24CA210999), G.G.’s funds at the Broad Institute and MGH. J.S.P. was partially funded by Independent Research Fund Denmark (12-126439 and 7016-00379) and The Danish Cancer Society (R124-A7869). R.B. received funds from the National Institutes of Health (U54CA143798, R01CA188228, R35GM127029, and R01CA215489). J.W. was partly funded by Independent Research Fund Denmark (4183-00233B and 8020-00282B) and Danish Cancer Society (R147-Rp12977). N.L.-B. acknowledges funding from the European Research Council consolidator grant 682398) and Spanish Ministry of Economy and Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The genomic landscape of 2,023 colorectal cancers

  • Cornish, Alex J.
  • Arnedo Pac, Claudia
  • López Bigas, Núria
  • Houlston, Richard S.
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2-9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11-13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care., R.S.H., I.P.M.T. and N.L.-B. are supported by the Wellcome Trust (214388), T.A.G. and A.S are supported by the Wellcome Trust (202778/B/16/Z). I.P.M.T. is supported by Cancer Research UK (C6199/A27327). R.S.H. is supported by Cancer Research UK (C1298/A8362). D.C.W. is supported by the NIHR Manchester Biomedical Research Centre (NIHR203308). A. Sottoriva is supported by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771 and DRCNPG-May21\100001). P.Q. and H.M.W. are supported by Cancer Research UK Grand Challenge Initiative (OPTIMISTICC C10674/A27140). P.Q. is also supported by Yorkshire Cancer Research L386 and is a National Institute of Health Senior Investigator. B.N was funded through the Cancer Research UK Birmingham Centre award (C17422/A25154). C.A.-P. was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011). L.B.A was supported by grants from the US National Institutes of Health, including NIEHS R01ES032547 and NCI R01CA269919. G.C. is supported by the Italian Association for Cancer Research (AIRC) under MFAG 2020-ID 24913. We acknowledge funding from the National Institute of Health (NCI U54 CA217376) to A.S and T.A.G. This work was also supported by a Wellcome Trust award to the Centre for Evolution and Cancer at the ICR (105104/Z/14/Z). D.N.C. is supported a by Cancer Research UK Advanced Clinician Scientist Fellowship award (C26642/A27963). D.N.C., D.C.W. and A.F. acknowledge support from the Oxford NIHR Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We are grateful to all participants and other individuals involved in the study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The repertoire of mutational signatures in human cancer

  • Alexandrov, Ludmil B.
  • López Bigas, Núria
  • PCAWG Consortium
Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature1. Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium2 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses3-15, enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated-but distinct-DNA damage, repair and/or replication mechanisms. By estimating the contribution of each signature to the mutational catalogues of individual cancer genomes, we revealed associations of signatures to exogenous or endogenous exposures, as well as to defective DNA-maintenance processes. However, many signatures are of unknown cause. This analysis provides a systematic perspective on the repertoire of mutational processes that contribute to the development of human cancer., This work was supported by Wellcome grant reference 206194 (M.R.S.), Singapore National Medical Research Council grants NMRC/CIRG/1422/2015 and MOH-000032/MOH-CIRG18may-0004 and the Singapore Ministry of Health via the Duke-NUS Signature Research Programmes (M.N.H., A.W.T.N., Y.W., A.B. and S.G.R.), US National Institute of Health Intramural Research Program Project Z1AES103266 (D.A.G.), the European Research Council Consolidator Grant 682398 (N.L.-B.), US National Cancer Institute U24CA143843 (D.A.W.) and Cancer Research UK Grand Challenge Award C98/A24032 (E.N.B., S.M.A.I., L.B.A. and M.R.S.). G.G and J.K were partially supported by the National Cancer Institute grants U24CA210999 and U24CA143845. G.G. was partially supported by the Paul C. Zamecnick, MD, Chair in Oncology at the Massachusetts General Hospital Cancer Center. N.J.H. and G.G. were partially supported by G.G.’s funds at the Broad Institute and Massachusetts General Hospital. N.J.H. was partially funded by the Molecular Biophysics Training Grant NIH/ NIGMS T32 GM008313 (PI: Venkatesh N. Murthy).We acknowledge the contributions of the many clinical networks across the ICGC and TCGA who provided samples and data to the PCAWG Consortium, and the contributions of the Technical Working Group and the Germline Working Group of the PCAWG Consortium for collation, realignment and harmonized variant calling of the cancer genomes used in this study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A compendium of mutational cancer driver genes

  • Martínez Jiménez, Francisco
  • Kranas, Hanna
  • Gonzalez Perez, Abel
  • López Bigas, Núria
  • Muiños, Ferran
  • Sentís, Inés
  • Deu Pons, Jordi
  • Reyes Salazar, Iker
  • Arnedo Pac, Claudia
  • Mularoni, Loris
  • Pich, Oriol
  • Bonet, José
A fundamental goal in cancer research is to understand the mechanisms of cell transformation. This is key to developing more efficient cancer detection methods and therapeutic approaches. One milestone towards this objective is the identification of all the genes with mutations capable of driving tumours. Since the 1970s, the list of cancer genes has been growing steadily. Because cancer driver genes are under positive selection in tumorigenesis, their observed patterns of somatic mutations across tumours in a cohort deviate from those expected from neutral mutagenesis. These deviations, which constitute signals of positive selection, may be detected by carefully designed bioinformatics methods, which have become the state of the art in the identification of driver genes. A systematic approach combining several of these signals could lead to a compendium of mutational cancer genes. In this Review, we present the Integrative OncoGenomics (IntOGen) pipeline, an implementation of such an approach to obtain the compendium of mutational cancer drivers. Its application to somatic mutations of more than 28,000 tumours of 66 cancer types reveals 568 cancer genes and points towards their mechanisms of tumorigenesis. The application of this approach to the ever-growing datasets of somatic tumour mutations will support the continuous refinement of our knowledge of the genetic basis of cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

OpenVariant: a toolkit to parse and operate multiple input file formats

  • Martínez-Millán, David
  • Brando, Federica
  • Grau, Miguel L.
  • Sánchez-Guixé, Mònica
  • López Elorduy, Carlos
  • Reyes-Salazar, Iker
  • Deu-Pons, Jordi
  • López Bigas, Núria
  • González-Pérez, Abel
Summary: Advances in high-throughput DNA sequencing technologies and decreasing costs have fueled the identification of small genetic variants (such as single nucleotide variants and indels) across tumors. Despite efforts to standardize variant formats and vocabularies, many sources of variability persist across databases and computational tools that annotate variants, hindering their integration within cancer genomic analyses. In this context, we present OpenVariant, an easily extendable Python package that facilitates seamless reading, parsing and refinement of diverse input file formats in a customizable structure, all within a single process. Availability and implementation: OpenVariant is an open-source package available at https://github.com/bbglab/openvariant. Documentation may be found at https://openvariant.readthedocs.io., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]. This project has received funding from the European Union’s Horizon Europe programme [grant agreement CGI-Clinics 101057509]. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociación Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). This work has also been funded by the Institute of Health Carlos III [project IMPaCT-Data, exp. IMP/00019], co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

  • Wagner, Alex H.
  • Tamborero Noguera, David
  • López Bigas, Núria
  • Variant Interpretation for Cancer Consortium
Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases., We acknowledge the contributions from members of GA4GH and specifically the Genotype to Phenotype Task Team for their numerous contributions leading to this study. We thank the VICC knowledgebase partners for their input in construction of the meta-knowledgebase and drafting of the paper, M. McCoy for his assistance in proofreading the manuscript and J. McMichael for his work in restyling Fig. 1. A.H.W. was supported by NIH National Cancer Institute (NCI) award F32CA206247 and National Human Genome Research Institute (NHGRI) award K99HG010157. B.W. was supported by NIH NHGRI award U54HG007990, NIH NCI R01CA180778 and Intel SRA-16-037. D.T.R. is a participant in the Berlin Institute of Health—Charité Clinical Scientist Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health, and was supported by grant nos. 031L0030E and 031L0023 awarded by the German Federal Ministry of Education and Research. D.I.R. and S.M. are supported by ClinGen, through the NHGRI awards U41HG006834, U41HG009649, U41HG009650 and U01HG007437. T.A. was supported by an award from Academy of Finland (grant no. 330857), Cancer Society of Finland. M.H. was supported by the Monarch Initiative NIH Office of Director award R24OD011883. J. Gao, D.C. and N.S. were supported by NIH NCI award P30CA008748. N.L.B. acknowledges funding from the European Research Council (consolidator grant 682398). M.L. was supported through the Medical Research Council—Cancer Research UK Stratification in Colorectal Cancer Program grant and Health Data Research UK Substantive Site grant. M.G. was supported by NIH NHGRI award R00HG007940 and a V Scholar Award from the V Foundation for Cancer Research. O.L.G., M.G. and the CIViC knowledgebase were supported by the NIH NCI awards U01CA209936 and U24CA237719 and a Cancer Moonshot funding opportunity, specifically an Activities to Promote Technology Research Collaborations for Cancer Research (Administrative Support) award.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reduced mutation rate in exons due to differential mismatch repair

  • Frigola, Joan
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • Muiños, Ferran
  • Gonzalez-Perez, Abel
  • López Bigas, Núria
While recent studies have identified higher than anticipated heterogeneity of mutation rate across genomic regions, mutations in exons and introns are assumed to be generated at the same rate. Here we find fewer somatic mutations in exons than expected from their sequence content and demonstrate that this is not due to purifying selection. Instead, we show that it is caused by higher mismatch-repair activity in exonic than in intronic regions. Our findings have important implications for understanding of mutational and DNA repair processes and knowledge of the evolution of eukaryotic genes, and they have practical ramifications for the study of evolution of both tumors and species., We acknowledge funding from Spanish Ministry of Economy and Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE), La Fundació la Marató de TV3, EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). R. Sabarinathan is supported by an EMBO Long-Term Fellowship (ALTF 568-2014) co-funded by the European Commission (EMBOCOFUND2012, GA-2012-600394) support from Marie Curie Actions. A.Gonzalez-Perez is supported by a Ramón y Cajal contract
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Whole-genome landscapes of major melanoma subtypes

  • Hayward, Nicholas K.
  • Wilmott, James S.
  • Waddell, Nicola
  • Johansson, Peter A.
  • Field, Matthew A.
  • Nones, Katia
  • Patch, Ann-Marie
  • Kakavand, Hojabr
  • Alexandrov, Ludmil B.
  • Burke, Hazel
  • Jakrot, Valerie
  • Kazakoff, Stephen
  • Holmes, Oliver
  • Leonard, Conrad
  • Sabarinathan, Radhakrishnan
  • Mularoni, Loris
  • Wood, Scott
  • Xu, Qinying
  • Waddell, Nick
  • Tembe, Varsha
  • Pupo, Gulietta M.
  • Paoli-Iseppi, Ricardo De
  • Vilain, Ricardo E.
  • Shang, Ping
  • Lau, Loretta M.S.
  • Dagg, Rebecca A.
  • Schramm, Sarah-Jane
  • Pritchard, Antonia
  • Dutton-Regester, Ken
  • Newell, Felicity
  • Fitzgerald, Anna
  • Shang, Catherine A.
  • Grimmond, Sean M.
  • Pickett, Hilda A.
  • Yang, Jean Y.
  • Stretch, Jonathan R.
  • Behren, Andreas
  • Kefford, Richard F.
  • Hersey, Peter
  • Long, Georgina V.
  • Cebon, Jonathan
  • Shackleton, Mark
  • Spillane, Andrew J.
  • Saw, Robyn P. M.
  • López Bigas, Núria
  • Pearson, John V.
  • Thompson, John F.
  • Scolyer, Richard A.
  • Mann, Graham J.
Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

  • Wagner, Alex H.
  • Walsh, Brian
  • Mayfield, Georgia
  • Tamborero, David
  • Sonkin, Dmitriy
  • Krysiak, Kilannin
  • Dienstmann, Rodrigo
Càncer: Investigació genètica, Cáncer; Investigación genética, Cancer; Genetics research, Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hotspot propensity across mutational processes

  • Arnedo Pac, Claudia
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
The sparsity of mutations observed across tumours hinders our ability to study mutation rate variability at nucleotide resolution. To circumvent this, here we investigated the propensity of mutational processes to form mutational hotspots as a readout of their mutation rate variability at single base resolution. Mutational signatures 1 and 17 have the highest hotspot propensity (5-78 times higher than other processes). After accounting for trinucleotide mutational probabilities, sequence composition and mutational heterogeneity at 10 Kbp, most (94-95%) signature 17 hotspots remain unexplained, suggesting a significant role of local genomic features. For signature 1, the inclusion of genome-wide distribution of methylated CpG sites into models can explain most (80-100%) of the hotspot propensity. There is an increased hotspot propensity of signature 1 in normal tissues and de novo germline mutations. We demonstrate that hotspot propensity is a useful readout to assess the accuracy of mutation rate models at nucleotide resolution. This new approach and the findings derived from it open up new avenues for a range of somatic and germline studies investigating and modelling mutagenesis., This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation has made available to the study. We acknowledge the technical contributions of Iker Reyes-Salazar and Loris Mularoni to HotspotFinder algorithm and annotations. NL-B acknowledges funding from the European Research Council (consolidator grant 682398) and the European Regional Development Fund/Spanish Ministry of Science, Innovation and Universities—Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Fundación Científica Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). This work has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMINENT) funded by Cancer Research UK (CGCATF-2021/100008), National Cancer Institute (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). CA-P was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Somatic and Germline Mutation Periodicity Follow the Orientation of the DNA Minor Groove around Nucleosomes

  • Pich, Oriol
  • Muiños, Ferran
  • Sabarinathan, Radhakrishnan
  • Reyes Salazar, Iker
  • González Pérez, Abel
  • López Bigas, Núria
Mutation rates along the genome are highly variable and influenced by several chromatin features. Here, we addressed how nucleosomes, the most pervasive chromatin structure in eukaryotes, affect the generation of mutations. We discovered that within nucleosomes, the somatic mutation rate across several tumor cohorts exhibits a strong 10 base pair (bp) periodicity. This periodic pattern tracks the alternation of the DNA minor groove facing toward and away from the histones. The strength and phase of the mutation rate periodicity are determined by the mutational processes active in tumors. We uncovered similar periodic patterns in the genetic variation among human and Arabidopsis populations, also detectable in their divergence from close species, indicating that the same principles underlie germline and somatic mutation rates. We propose that differential DNA damage and repair processes dependent on the minor groove orientation in nucleosome-bound DNA contribute to the 10-bp periodicity in AT/CG content in eukaryotic genomes.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers

  • Arnedo Pac, Claudia
  • Mularoni, Loris
  • Muiños, Ferran
  • Gonzalez-Perez, Abel
  • López Bigas, Núria
Motivation: Identification of the genomic alterations driving tumorigenesis is one of the main goals in oncogenomics research. Given the evolutionary principles of cancer development, computational methods that detect signals of positive selection in the pattern of tumor mutations have been effectively applied in the search for cancer genes. One of these signals is the abnormal clustering of mutations, which has been shown to be complementary to other signals in the detection of driver genes. Results: We have developed OncodriveCLUSTL, a new sequence-based clustering algorithm to detect significant clustering signals across genomic regions. OncodriveCLUSTL is based on a local background model derived from the simulation of mutations accounting for the composition of tri- or penta-nucleotide context substitutions observed in the cohort under study. Our method can identify known clusters and bona-fide cancer drivers across cohorts of tumor whole-exomes, outperforming the existing OncodriveCLUST algorithm and complementing other methods based on different signals of positive selection. Our results indicate that OncodriveCLUSTL can be applied to the analysis of non-coding genomic elements and non-human mutations data. Availability and implementation: OncodriveCLUSTL is available as an installable Python 3.5 package. The source code and running examples are freely available at https://bitbucket.org/bbglab/oncodriveclustl under GNU Affero General Public License. Supplementary information: Supplementary data are available at Bioinformatics online., This work was supported by funding from the Spanish Ministry of Economy and Competitiveness [SAF2015-66084-R, MINECO/FEDER, UE] and by the European Research Council [Consolidator Grant 68239]. IRB Barcelona is the recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). A.G.-P. is supported by a Ramón y Cajal contract from the Spanish Ministry of Economy and Competitiveness [RYC-2013-1455]. C.A.-P. is supported by “la Caixa” Foundation (ID 100010434) with code [LCF/BQ/ES18/11670011].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

  • Sánchez-Guixé, Mònica
  • Muiños, Ferran
  • Pinheiro Santin, Morena
  • González-Huici, Víctor
  • Rodríguez-Hernández, Carlos
  • Avgustinova, Alexandra
  • Lavarino, Cinzia
  • González-Pérez, Abel
  • Mora, Jaume
  • López Bigas, Núria
Pediatric cancers are rare diseases, and children without known germline predisposing conditions who develop a second malignancy during developmental ages are extremely rare. We present four such clinical cases and, through whole-genome and error-correcting ultra-deep duplex sequencing of tumor and normal samples, we explored the origin of the second malignancy in four children, uncovering different routes of development. The exposure to cytotoxic therapies was linked to the emergence of a secondary acute myeloid leukemia. A common somatic mutation acquired early during embryonic development was the driver of two solid malignancies in another child. In two cases, the two tumors developed from completely independent clones diverging during embryogenesis. Importantly, we demonstrate that platinum-based therapies contributed at least one order of magnitude more mutations per day of exposure than aging to normal tissues in these children., N. Lopez-Bigas acknowledges funding from the European Research Council (consolidator grant 682398). M. Sanchez-Guixe was supported by a postdoctoral contract with the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). This project was supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI 10.13039/501100011033/. It has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMI­NENT) funded by Cancer Research UK (CGCATF-2021/100008), NCI (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). We are grateful to the Band of Parents at Hospital Sant Joan de Déu Barcelona for supporting the overall research activities of the developmental tumor laboratory, PCCB, and for having generously contributed with their samples. This study would have been impossible to reach without this contribution.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero, David
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Deu-Pons, Jordi
  • Schroeder, Michael P.
  • Vivancos, Ana|||0000-0003-2888-6512
  • Rovira, Ana|||0000-0003-1301-2599
  • Tusquets, Ignasi
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rodón Ahnert, Jordi
  • Tabernero, Josep|||0000-0002-2495-8139
  • De Torres, Carmen
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org. The online version of this article (10.1186/s13073-018-0531-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The evolution of hematopoietic cells under cancer therapy

  • Pich, Oriol|||0000-0002-1956-1882
  • Cortés Bullich, Albert|||0000-0002-6260-901X
  • Muiños, Ferran|||0000-0002-4651-4168
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
Chemotherapies may increase mutagenesis of healthy cells and change the selective pressures in tissues, thus influencing their evolution. However, their contributions to the mutation burden and clonal expansions of healthy somatic tissues are not clear. Here, exploiting the mutational footprint of some chemotherapies, we explore their influence on the evolution of hematopoietic cells. Cells of Acute Myeloid Leukemia (AML) secondary to treatment with platinum-based drugs show the mutational footprint of these drugs, indicating that non-malignant blood cells receive chemotherapy mutations. No trace of the 5-fluorouracil (5FU) mutational signature is found in AMLs secondary to exposure to 5FU, suggesting that cells establishing the leukemia could be quiescent during treatment. Using the platinum-based mutational signature as a barcode, we determine that the clonal expansion originating the secondary AMLs begins after the start of the cytotoxic treatment. Its absence in clonal hematopoiesis cases is consistent with the start of the clonal expansion predating the exposure to platinum-based drugs.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites

  • Sabarinathan, Radhakrishnan
  • Lopez-Bigas, Nuria
  • Frigola Rissech, Joan
  • Gonzalez-Perez, Abel
Llocs d’unió; Dany en l'ADN; Factor de transcripció, Sitios de unión; Daño en el ADN; Factor de transcripcion, Binding sites; Dna damage; Transcription factor, An abnormally high rate of UV-light related mutations appears at transcription factor binding sites (TFBS) across melanomas. The binding of transcription factors (TFs) to the DNA impairs the repair of UV-induced lesions and certain TFs have been shown to increase the rate of generation of these lesions at their binding sites. However, the precise contribution of these two elements to the increase in mutation rate at TFBS in these malignant cells is not understood. Here, exploiting nucleotide-resolution data, we computed the rate of formation and repair of UV-lesions within the binding sites of TFs of different families. We observed, at certain dipyrimidine positions within the binding site of TFs in the Tryptophan Cluster family, an increased rate of formation of UV-induced lesions, corroborating previous studies. Nevertheless, across most families of TFs, the observed increased mutation rate within the entire DNA region covered by the protein results from the decreased repair efficiency. While the rate of mutations across all TFBS does not agree with the amount of UV-induced lesions observed immediately after UV exposure, it strongly agrees with that observed after 48 h. This corroborates the determinant role of the impaired repair in the observed increase of mutation rate., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]; Spanish Ministry of Economy and Competitiveness [SAF2015-66084-R, MINECO/FEDER to U.E.]; IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya); R.S. acknowledges funding support from the National Centre for Biological Sciences (NCBS-TIFR), Bangalore, India. Funding for open access charge: Spanish Ministry of Economy and Competitiveness.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

  • Wagner, Alex H.
  • Walsh, Brian
  • Mayfield, Georgia
  • Tamborero, David
  • Sonkin, Dmitriy
  • Krysiak, Kilannin
  • Dienstmann, Rodrigo
Càncer: Investigació genètica, Cáncer; Investigación genética, Cancer; Genetics research, Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases.